Citigroup
KLRS

Citigroup’s Kalaris Therapeutics KLRS Stock Holding History

Citigroup’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50.2K Buy
8,703
+8,702
+870,200% +$77.2K ﹤0.01% 4528
2025
Q4 		$8 Hold
1
– – ﹤0.01% 5830
2025
Q3 		$6 Buy
+1
New +$3 ﹤0.01% 5982
2025
Q1 		– Sell
-7
Closed -$66 – 6065
2024
Q4 		$66 Sell
7
-36
-84% -$545 ﹤0.01% 5706
2024
Q3 		$800 Sell
43
-289
-87% -$5.05K ﹤0.01% 5458
2024
Q2 		$5.53K Sell
332
-122
-27% -$2.15K ﹤0.01% 5246
2024
Q1 		$7.89K Buy
454
+129
+40% +$2.1K ﹤0.01% 5251
2023
Q4 		$5.08K Buy
325
+259
+392% +$10.2K ﹤0.01% 5331
2023
Q3 		$3.28K Sell
66
-608
-90% -$41.4K ﹤0.01% 4834
2023
Q2 		$52.7K Buy
674
+563
+507% +$53.5K ﹤0.01% 4612
2023
Q1 		$10.1K Sell
111
-2
-2% -$255 ﹤0.01% 4726
2022
Q4 		$13.3K Buy
113
+1
+0.9% +$170 ﹤0.01% 4740
2022
Q3 		$20K Sell
112
-167
-60% -$26K ﹤0.01% 4754
2022
Q2 		$25K Buy
279
+17
+6% +$1.78K ﹤0.01% 4879
2022
Q1 		$41K Sell
262
-2,234
-90% -$446K ﹤0.01% 4817
2021
Q4 		$743K Buy
2,496
+1,100
+79% +$510K ﹤0.01% 3523
2021
Q3 		$804K Sell
1,396
-3,497
-71% -$1.62M ﹤0.01% 3252
2021
Q2 		$2.22M Buy
4,893
+816
+20% +$421K ﹤0.01% 2590
2021
Q1 		$2.19M Buy
4,077
+3,812
+1,438% +$3.2M ﹤0.01% 2429
2020
Q4 		$234K Buy
265
+228
+616% +$175K ﹤0.01% 4875
2020
Q3 		$24K Buy
+37
New +$25.3K ﹤0.01% 6064

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Citigroup's KLRS Position: Q1 2026 in Review

Citigroup increased its Kalaris Therapeutics (KLRS) stake by 870,200% in Q1 2026, buying an estimated $77.2K and bringing the position to 8,703 shares worth $50.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4528.

Citigroup first reported a position in KLRS in Q3 2020 and has held it in 21 quarters since. The position peaked at $2.22M in Q2 2021. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Citigroup held 8,703 shares of Kalaris Therapeutics worth $50.2K as of Q1 2026.
  • Citigroup bought 8,702 Kalaris Therapeutics shares in Q1 2026, an estimated $77.2K.
  • Kalaris Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4528 holding.
  • Citigroup first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • Citigroup's Kalaris Therapeutics position peaked at $2.22M in Q2 2021.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.